Signs point to yes, but it's still early in the game.
Compare MRK Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Merck & Co.
News & Analysis: Merck & Co.
Molnupiravir seems likely to shake up the COVID-19 antibody therapy market.
These big drugmakers could soon compete against each other with oral COVID-19 therapies.
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.
Merck will pick up a promising pipeline candidate with the deal.
The drugmaker's recent struggles present a terrific buying opportunity.
Merck, Pfizer, and Atea are set to do battle next year in the COVID-19 pill market.
Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector.
Even so, they're taking a big dive Friday.
The market's caution when it comes to the healthcare sector presents a buying opportunity for these two stocks.